Can GSK and Altius reshape the way drug development is conducted?




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Can GSK and Altius reshape the way drug development is conducted?
Released on: January 08, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Lon Cardon, GSK, and John Stamatoyannopoulos, University of Washington, discuss the recent launch of Altius Institute for Biomedical Sciences.
  • Summary
  • Transcript
  • Company
Lon Cardon, GSK, and John Stamatoyannopoulos, University of Washington, discuss the recent launch of Altius Institute for Biomedical Sciences. Funded by GSK, Altius is an independent non-profit research institute focused on genomic research.
Lon Cardon, GSK, and John Stamatoyannopoulos, University of Washington, discuss the recent launch of Altius Institute for Biomedical Sciences. Funded by GSK, Altius is an independent non-profit research institute focused on genomic research.
GlaxoSmithKline (GSK)
GSK is the world's second largest pharmaceutical company, by employees; and a research-based company with a wide portfolio of pharmaceutical products covering anti-infectives, central nervous system, respiratory, gastro-intestinal/metabolic, oncology, and vaccines products. It also has a Consumer Healthcare operation comprising leading oral healthcare products, nutritional drinks, and over the counter medicines.